act-001
Small moleculeexperimental
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 22, 2021 (NCT05053880)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)C[C@H]1[C@@H]2CCC(C)=C3CC[C@@](C)(O)[C@@H]3[C@H]2OC1=O- Mol. weight
- 293.4012 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS580BNQ45EO ↗
- ChEMBLCHEMBL2220079 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06838676 | Phase 2 | Jul 31, 2025 | Accendatech USA Inc., Ohio State University, University of Cincinnati, University of New South Wales |
| NCT06894225 | Phase 2 | Apr 30, 2025 | National Neuroscience Institute |
| NCT05053880 | Phase 1/Phase 2 (Phase 2) | Sep 22, 2021 | Accendatech USA Inc., Avance Clinical Pty Ltd., C3 Research Associates |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Accendatech USA Inc. | For profit | 2 | 1 | 1 | 2021 |
| Avance Clinical Pty Ltd. | For profit | 1 | 0 | 1 | 2021 |
| C3 Research Associates | For profit | 1 | 0 | 1 | 2021 |
| National Neuroscience Institute | Government | 1 | 1 | 1 | 2025 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of New South Wales | Academic/Hospital | 1 | 0 | 1 | 2025 |
7 organizations
Page 1 / 1